PMID- 28612913
OWN - NLM
STAT- MEDLINE
DCOM- 20180130
LR  - 20201216
IS  - 1897-4279 (Electronic)
IS  - 0022-9032 (Linking)
VI  - 75
IP  - 10
DP  - 2017
TI  - The usefulness of sST2 and galectin-3 as novel biomarkers for better risk 
      stratification in hypertrophic cardiomyopathy.
PG  - 997-1004
LID - 10.5603/KP.a2017.0118 [doi]
AB  - BACKGROUND: Estimation of sudden cardiac death (SCD) risk is an integral part of 
      clinical management of patients with hypertrophic cardiomyopathy (HCM). 
      Identification of novel biomarkers of this disease can provide additional 
      criteria for SCD risk stratification. Soluble suppression of tumourigenicity 
      (sST2) and galectin-3 (Gal-3) are useful biomarkers for prognosis of heart 
      failure (HF). Both of them appear to mediate cardiac fibrosis - an important 
      pathogenetic process in HCM. Data about sST2 and Gal-3 usefulness in patients 
      with HCM are limited. AIM: The aim of this study was to evaluate sST2 and Gal-3 
      as potential novel biomarkers for better risk stratification in hypertrophic 
      cardiomyopathy. METHODS: Serum sST2 and serum Gal-3 levels were measured in 57 
      patients with HCM and in 18 healthy controls. The patients with HCM underwent 
      routine evaluation including medical history, physical examination, blood tests 
      (including N-terminal pro-B-type natriuretic peptide [NT-proBNP] and 
      high-sensitivity cardiac troponin T [hs-cTnT] measurements), 12-lead 
      electrocardiography (ECG), 48-h Holter monitoring and two-dimensional (2D) 
      echocardiography with the assessment of the maximal left ventricular wall 
      thickness, left atrial diameter, maximal left ventricular outflow tract gradient, 
      and left ventricular ejection fraction. Risk of SCD at five years according to 
      HCM SCD-risk calculator was evaluated. The control group underwent ECG, 2D 
      echocardiography, and NT-proBNP measurements to exclude asymptomatic heart 
      disease. RESULTS: Concentrations of sST2 and Gal-3 were significantly higher in 
      patients with HCM than in controls (14.9 +/- 5.8 ng/mL vs. 11.7 +/- 3.3 ng/mL, p = 
      0.03 and 8.4 ng/mL [6.8-10.0] vs. 6.2 ng/mL [5.8-7.7], p = 0.005, respectively). 
      Levels of sST2 and Gal-3 were considerably different in the New York Heart 
      Association (NYHA) groups (p = 0.008, p = 0.009, respectively). Patients who 
      presented non-sustained ventricular tachycardia (nsVT) on 48-h Holter monitoring 
      had higher levels of sST2 (19.1 ng/mL [12.2-24.2] vs. 13.2 ng/mL [10.0-17.1], p = 
      0.02). There were no significant relationships between sST2 and Gal-3 levels and 
      HCM SCD-risk, history of syncope presence, family history of SCD, and 
      echocardio-graphic parameters. CONCLUSIONS: Gal-3 levels and sST2 levels were 
      higher in patients with HCM than in the control group. There were significant 
      differences in Gal-3 levels between NYHA classes, but no correlations between 
      Gal-3 levels and other parameters were found. Apart from differences in sST2 
      levels between NYHA classes, we demonstrated higher levels of sST2 in patients 
      with nsVT. These findings suggest that sST2 may be useful as an additional 
      biomarker for better risk stratification in hypertrophic cardiomyopathy.
FAU - Gawor, Monika
AU  - Gawor M
AD  - Institute of Cardiology, Warsaw, Poland. mgawor@ikard.pl.
FAU - Spiewak, Mateusz
AU  - Spiewak M
FAU - Janas, Jadwiga
AU  - Janas J
FAU - Kozuch, Katarzyna
AU  - Kozuch K
FAU - Wrobel, Aleksandra
AU  - Wrobel A
FAU - Mazurkiewicz, Lukasz
AU  - Mazurkiewicz L
FAU - Baranowski, Rafal
AU  - Baranowski R
FAU - Marczak, Magdalena
AU  - Marczak M
FAU - Grzybowski, Jacek
AU  - Grzybowski J
LA  - eng
PT  - Journal Article
DEP - 20170614
PL  - Poland
TA  - Kardiol Pol
JT  - Kardiologia polska
JID - 0376352
RN  - 0 (Biomarkers)
RN  - 0 (Galectin 3)
RN  - 0 (IL1RL1 protein, human)
RN  - 0 (Interleukin-1 Receptor-Like 1 Protein)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Cardiomyopathy, Hypertrophic/blood/*diagnosis
MH  - Female
MH  - Galectin 3/*blood
MH  - Humans
MH  - Interleukin-1 Receptor-Like 1 Protein/*blood
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Risk Assessment
OTO - NOTNLM
OT  - biomarker
OT  - galectin-3 (Gal-3)
OT  - hypertrophic cardiomyopathy
OT  - soluble suppression of tumourigenicity (sST2)
EDAT- 2017/06/15 06:00
MHDA- 2018/01/31 06:00
CRDT- 2017/06/15 06:00
PHST- 2017/03/24 00:00 [received]
PHST- 2017/05/17 00:00 [accepted]
PHST- 2017/05/07 00:00 [revised]
PHST- 2017/06/15 06:00 [pubmed]
PHST- 2018/01/31 06:00 [medline]
PHST- 2017/06/15 06:00 [entrez]
AID - VM/OJS/KP/11278 [pii]
AID - 10.5603/KP.a2017.0118 [doi]
PST - ppublish
SO  - Kardiol Pol. 2017;75(10):997-1004. doi: 10.5603/KP.a2017.0118. Epub 2017 Jun 14.